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a b s t r a c t
Androgen receptor (AR) signaling initiates mouse prostate development by stimulating prostate ductal
bud formation and specifying bud patterns. Curiously, however, prostatic bud initiation lags behind the
onset of gonadal testosterone synthesis by about three days. This study’s objective was to test the
hypothesis that DNA methylation controls the timing and scope of prostate ductal development by
regulating Ar expression in the urogenital sinus (UGS) from which the prostate derives. We determined
that Ar DNA methylation decreases in UGS mesenchyme during prostate bud formation in vivo and that
this change correlates with decreased DNA methyltransferase expression in the same cell population
during the same time period. To examine the role of DNA methylation in prostate development, fetal
UGSs were grown in serum-free medium and 5 alpha dihydrotestosterone (DHT) and the DNA
methylation inhibitor 50-aza-20-deoxycytidine (5AzadC) were introduced into the medium at speciﬁc
times. As a measure of prostate development, in situ hybridization was used to visualize and count
Nkx3-1 mRNA positive prostatic buds. We determined that inhibiting DNA methylation when prostatic
buds are being speciﬁed, accelerates the onset of prostatic bud development, increases bud number, and
sensitizes the budding response to androgens. Inhibition of DNA methylation also reduces Ar DNA
methylation in UGS explants and increases Ar mRNA and protein in UGS mesenchyme and epithelium.
Together, these results support a novel mechanism whereby Ar DNA methylation regulates UGS
androgen sensitivity to control the rate and number of prostatic buds formed, thereby establishing a
developmental checkpoint.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Precisely timed hormonal cues mediate several crucial devel-
opmental transitions such as metamorphosis in invertebrates and
amphibians (Kulkarni and Buchholz, 2014; Di Cara and King-Jones,
2013), molting in insects (Ono, 2014; Suzuki et al., 2013), and
growth and puberty in mammals (Di Cara and King-Jones, 2013;
Kurian et al., 2012; Walker et al., 2013). During mouse prostate
ductal development, precisely timed androgenic cues guide a
series of morphogenetic events that include prostatic bud speci-
ﬁcation (15–16 days post coitus, dpc), initiation (16–18 dpc),
elongation (18þ dpc), and branching morphogenesis (birth-
postnatal day 15) (Vezina et al., 2008; Sugimura et al., 1986). Our
research has been focused on elucidating mechanisms of prostatic
bud formation.
Androgens initiate prostatic bud formation by binding and
activating androgen receptors (ARs) in urogenital sinus (UGS)
mesenchyme during prostatic bud speciﬁcation (Allgeier et al.,
2010; Lasnitzki and Mizuno, 1980). ARs are especially abundant in
a subpopulation of mouse UGS mesenchymal cells known as
lamina propria mesenchyme. Radiolabeled testosterone binding
in this cell population is detectable beginning around 15 dpc
(Takeda et al., 1987) and coincides with onset of androgen
responsive steroid 5 alpha reductase type 2 (Srd5a2) and Wnt
inhibitor factor 1 (Wif1) mRNA expression (Abler et al., 2011; Keil
et al., 2012). However, mouse prostate development lags behind
the onset of gonadal testosterone synthesis and AR binding by
several days, a feature shared by other mammalian species
(Wilson et al., 2003). Mouse testicular androgen synthesis begins
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at 13 dpc but prostate bud outgrowth does not begin until three
days later, at 16 dpc (Lin et al., 2003). The lag is not due to the time
it takes nascent testicular androgens to reach the UGS, or to
accumulate in the UGS at sufﬁcient concentrations, because it
cannot be accelerated in vitro by growing UGSs in medium
containing physiological or supra-physiological androgen concen-
trations (Lasnitzki and Mizuno, 1977). Additionally, the lag
between androgen synthesis and prostatic bud formation is not
likely due to the absence of cell types capable of responding to
androgenic signals and forming prostatic buds. NK-3 transcription
factor locus 1 (Nkx3-1), considered the earliest marker of prostate
identity, is detectable in mouse UGS epithelium as early as 15 dpc,
about one day before the ﬁrst prostatic buds are present (Bhatia-
Gaur et al., 1999). Further, lineage tracing experiments at 14 dpc
reveal a subpopulation of sonic hedgehog (Shh) expressing UGS
epithelial cells that contribute to developing prostate bud epithe-
lium (Mehta et al., 2013).
We hypothesized that DNA methylation may function as a
molecular switch controlling the transition from prostatic bud
speciﬁcation to initiation. DNA methyltransferases (Dnmts) cata-
lyze addition of a methyl group to the 50 position of deoxycytidine,
which can inﬂuence chromatin conformation and gene expression
(Jaenisch and Bird, 2003). The Dnmt mRNA expression pattern is
reorganized between prostatic bud speciﬁcation and initiation.
While Dnmts predominate in UGS mesenchyme during prostatic
bud speciﬁcation, they are more noticeable in UGS epithelium
during bud initiation and early branching morphogenesis (Keil
et al., 2013). This temporal change in Dnmt expression coincides
with an increase in UGS mesenchymal Ar mRNA expression
(Takeda and Chang, 1991). These previous observations led us to
hypothesize that DNMT actions may converge on the Ar to regulate
its expression, thereby modulating UGS androgen responsiveness
and the onset of prostatic bud formation.
In this study, we found that DNA methylation regulates UGS
androgen sensitivity and the timing of prostatic bud formation.
The abundance of Ar promoter DNA methylation in UGS mesench-
yme decreases during prostatic outgrowth in vivo, coinciding with
decreased Dnmt expression over the same period. Administration
of a DNA methylation inhibitor during prostatic bud formation
in vitro accelerates prostatic bud formation and increases bud
number. The DNA methylation inhibitor also acts on the UGS
in vitro by reducing Ar DNA methylation, increasing Ar mRNA and
protein abundance, and increasing sensitivity of prostatic bud
formation to androgens. These results led us to conclude that a
regulatory region of the Ar gene is likely methylated prior to
prostate bud formation to dampen AR expression and protect
against precocious development; DNA methylation is then
decreased allowing for androgen-dependent onset of prostatic
bud formation. Our ﬁndings are important because they provide
new testable mechanisms for how prostate development is tem-
porally regulated and how environmental and estrogenic chemi-
cals may perturb prostate development.
Materials and methods
Animals
Wild type C57BL/6J mice were purchased from Jackson Labora-
tory (Bar Harbor, ME). Mice were housed in polysulfone cages
containing corn cob bedding and were maintained on a 12 h light
and dark cycle at 2575 1C and 20–50% relative humidity. Feed
(Diet 2019 for males and Diet 7002 for pregnant females, Harlan
Teklad, Madison, WI) and water were available ad libitum. All
procedures were approved by the University of Wisconsin Animal
Care and Use Committee and conducted in accordance with the
NIH Guide for the Care and Use of Laboratory Animals. To obtain
timed-pregnant dams, females were paired overnight with males.
The next morning was considered 0 days post coitus (dpc).
Pregnant dams were euthanized by CO2 asphyxiation and UGS
tissue collected from resulting fetuses. For tissue separations 14
and 17 dpc UGS mesenchyme was enzymatically and mechanically
separated from UGS epithelium and homogenized as described
previously (Vezina et al., 2008).
In situ hybridization (ISH)
ISH was conducted on whole mount tissues as described
previously (Abler et al., 2011; Keil et al., 2012). Detailed protocols
for PCR-based riboprobe synthesis are available at www.gudmap.
org. Staining patterns were assessed in at least three litter
independent tissues per group. Tissues were processed as a single
experimental unit to allow for qualitative comparisons among
biological replicates and treatment groups.
Organ culture
Male or female 14 dpc mouse urogenital sinus (UGS) explants
were placed on 0.4-μm Millicell-CM ﬁlters (Millipore, Billerica,
MA) and cultured as described previously (Vezina et al., 2008).
Medium was supplemented with one or all of the following: 0.01–
10 nM ﬁnal concentration 5α-dihydrotestosterone (DHT) dissolved
in ethanol (0.1%), 0.1% dimethyl sulfoxide (DMSO, vehicle control)
or DMSO containing 5 μM 5-aza-20-deoxycytidine (5AzadC, A3635,
Sigma-Aldrich, St. Louis, MO). Medium and supplements were
changed every 2 days.
Immunohistochemistry (IHC)
Immunoﬂuorescent staining of ISH-stained tissues and parafﬁn
sections was performed as described previously (Abler et al., 2011;
Keil et al., 2012). Primary antibodies were diluted as follows: 1:200
rabbit anti-CDH1 (3195, Cell Signaling Technology, Beverly, MA),
1:250 mouse anti-CDH1 (610181, BD Transduction Laboratories,
San Jose, CA) 1:50 mouse anti-KRT14 (ms-115-p0, Thermo Fisher
Scientiﬁc), 1:250 rabbit anti-AR (sc-816, Santa Cruz Biotechnology,
Santa Cruz, CA), 1:200 rabbit anti-DNMT1 (5032, Cell Signaling
Technology). Secondary antibodies were diluted as follows: 1:250
Dylight 549-conjugated goat anti-rabbit IgG (111-507-003, Jackson
ImmunoResearch, West Grove, PA), 1:250 Dylight 488-conjugated
goat anti-rabbit IgG (111-487-003, Jackson ImmunoResearch) and
1:250 Dylight 488-conjugated goat anti-mouse IgG (115-487-003,
Jackson ImmunoResearch). Immunoﬂuorescently labeled tissues
were counterstained with 40,6-diamidino-2-phenylindole, dilac-
tate (DAPI), and mounted in anti-fade medium (phosphate buf-
fered saline containing 80% glycerol and 0.2% n-propyl gallate).
Whole mount immunohistochemistry was performed as described
previously (Keil et al., 2012). Primary antibody was diluted 1:750
rabbit anti-CDH1 and secondary antibody was diluted 1:500 biotin
conjugated goat anti-rabbit IgG (BA-1000, Vector, Burlingame, CA).
Methylated DNA immunoprecipitation (MeDIP)
MeDIP was conducted as described previously (Keil et al.,
2014). UGS explants were pooled (5–6 tissues/pool) and each
experimental group consisted of ﬁve pools. Real time quantitative
PCR (QPCR) was performed as described previously (Keil et al.,
2012) using gene speciﬁc primers for mouse Ar: 50-AGAGACGAG-
GAGGCAGGATAAG-30 and 50-CGCTCCTCGATAGGTCTTGG-30 (Entrez
gene ID 11835) spanning the region þ58 bp to 84 bp of the
transcription start site (TSS).
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Pyrosequencing of bisulﬁte converted DNA
Genomic DNA was isolated using the Qiagen DNeasey Blood and
Tissue Kit according to manufacturer’s instructions. Bisulﬁte conver-
sion of DNA was performed using the Qiagen Epitect Bisulﬁte Kit per
manufacturer’s instructions. Calibration standards of highly methy-
lated DNA, prepared as described previously (Tost and Gut, 2007), and
unmethylated DNA, prepared using the Qiagen REPLI-g Mini Kit
according to manufacturer’s instructions, were used as controls. One
microgram of bisulﬁte treated DNA was used to generate PCR
ampliﬁed templates for pyrosequencing. Fifty microliter PCR reactions
consisted of bisulﬁte DNA, 1 GoTaq Buffer, 0.4 mM dNTP, 0.3 uM
primers and 0.05 U/mL GoTaq (Promega, Madison, WI) and the follow-
ing primers generated by PyroMark 2.0 software: Ar (NC_000086.7)
(þ209 toþ230 of Ar TSS) forward 50-GTTTAAGGATGGAGGTGTAGT-
TAG-30, and biotinylated reverse 50-AAACCAAATAACCTATAAAACCTC-
TAAT-30. PCR conditions were as follows: 95 1C5min, followed by
45 cycles of 95 1C30 s, 50 1C30 s, and 72 1C1min followed by
72 1C for 5 min. Ten microliters of biotinylated PCR product was used
for each sequencing assay, which included the following sequencing
primer: 50-ATAGTAGAGGTAGGAGATTAGTTT-30. Pyrosequencing was
performed using PyroMark Gold Q96 reagents (Biotage, Uppsala,
Sweden) and streptavidin sepharose beads (GE, Cat# 17-5113-01) with
the PSQ HS 96 Pyrosequencer. Percent methylation of each CpG was
determined using Pyro Q-CpG Software (Biotage, Uppsala, Sweden).
Average methylation at each CpG was calculated from three technical
replicates with at least three litter independent sample pools
per group.
Real time quantitative PCR (QPCR)
QPCR was conducted as described previously (Keil et al., 2012)
on UGS explant pools (5–6 tissues/pool) with ﬁve pools per
experimental treatment group using the following gene speciﬁc
primers: Ar, 50-GATGGTATTTGCCATGGGTTG-30 and 50-GGCTGTA-
CATCCGAGACTTGTG-30 and peptidyl prolyl isomerase a (Ppia),
50-TCTCTCCGTAGATGGACCTG-30 and 50-ATCACGGCCGATGAC-
GAGCC-30. Relative mRNA abundance was determined by the
ΔΔCt method as described previously (Livak and Schmittgen,
2001) and normalized to Ppia abundance.
Statistical analyses
For prostatic bud counting, UGSs were stained by ISH for Nkx3-1
mRNA and counted as described previously (Keil et al., 2012). For
immunolabeled cell counting, AR positive cells were counted in at
least two sections from three litter independent tissues per treat-
ment group. Statistical analysis was performed using R version
2.13.1. Homogeneity of variance was determined using Bartlett’s
test. Student’s T-test, one way analysis of variance (ANOVA),
followed by Tukey’s Honest Signiﬁcant Difference (HSD) or analysis
of covariance (ANCOVA) tests were used to identify signiﬁcant
differences (pr0.05) between or among treatment groups.
Results
DNA methylation regulates prostatic ductal development by
restricting bud formation
We previously reported that the spatial pattern of DNA methyl-
transferase 1 (Dnmt1) mRNA changes during early prostate devel-
opment (Keil et al., 2013). Here, we demonstrate that DNMT1
protein follows the same spatiotemporal expression pattern as its
mRNA. During prostatic bud speciﬁcation, DNMT1 protein predo-
minates in UGS mesenchyme (Fig. 1A). During prostatic bud initia-
tion and outgrowth, DNMT1 protein is diminished in UGS
mesenchyme and is abundant in UGS epithelium and prostatic
buds (Fig. 1B). This change in DNMT1 protein expression pattern
over the course of prostatic bud formation led us to hypothesize
DNA methylation elicits different actions at each stage of prostatic
bud formation. To elucidate the early stage actions of DNA methyla-
tion, we pulse-treated UGSs with a DNA methylation inhibitor
during speciﬁcation (when DNMT1 predominates in mesenchyme)
and examined subsequent bud formation. UGSs were collected from
14 dpc male mouse fetuses (prior to prostatic formation), grown for
two days in androgen-free medium containing DNA methylation
inhibitor 50-aza-20-deoxycytidine (5 μM, 5AzadC) or vehicle (0.1%
DMSO) alone, then grown for an additional ﬁve days in medium
containing androgen (10 nM dihydrotestosterone, DHT) but no DNA
methylation inhibitor (Fig. 2A). UGS explants were stained by ISH to
visualize the prostate marker, NK-3 transcription factor, locus 1
(Nkx3-1) (Keil et al., 2012; Bieberich et al., 1996; Sciavolino et al.,
1997) and by IHC to visualize UGS epithelium so that prostatic buds
could be counted. UGS explants cultured in the presence of DNA
methylation inhibitor during the ﬁrst two days of a seven day
culture period formed a greater number of buds compared to
controls (Fig. 2B and C).
We next tested whether inhibition of DNA methylation aug-
ments prostatic bud formation speciﬁcally in male UGS, or
Fig. 1. DNMT1 protein abundance diminishes in the mesenchyme during prostate development. (A,a) 14 dpc and (B,b) 17 dpc lower urinary tract sagittal sections were
stained by immunohistochemistry to visualize DNMT1 (red) protein and all epithelium E-cadherin (CDH1, green). Cell nuclei were stained with DAPI. Insets represent
magniﬁed images. Abbreviations: E, epithelium; M, mesenchyme.
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whether this action is generalizable to both male and female UGS.
Although male and female UGS development differs in vivo, female
UGSs can be induced by exogenous androgens to form prostatic
buds in a pattern that approximates bud formation in males
(Cunha, 1975). Female UGS explants grown in the presence of
5AzadC during the ﬁrst two days of a seven day culture period also
formed a greater number of buds compared to controls
(Supplemental Fig. 1A and B) and formed a similar number of
buds compared to male UGSs grown in the presence of 5AzadC
during the ﬁrst two days of a seven day culture period
(Supplemental Fig. 1C). Both male and female UGSs grown in the
presence of 5AzadC during the ﬁrst two days of a seven day culture
have similar histology (Supplemental Fig. 1D) and appear to have
shorter buds compared to control UGSs, a phenotype consistent
with that previously reported (Keil et al., 2014). Together these
results are consistent with DNA methylation functioning as a
general mechanism to reﬁne androgen dependent prostatic devel-
opment by restricting the number of prostatic buds formed.
DNA methylation acts during early development to control prostatic
bud formation
The DNMT1 protein expression pattern changes from UGS
mesenchyme dominant to UGS epithelium dominant during the
period spanning mouse prostatic bud speciﬁcation, initiation and
outgrowth (Fig. 1). To test whether inhibition of DNA methylation
augments prostatic bud formation during all stages of prostatic
bud formation, or exclusively during the speciﬁcation stage when
DNMT1 predominates in UGS mesenchyme, male 14 dpc UGS
explants were pulse-treated with 5AzadC during the ﬁrst two
days (prior to bud outgrowth, during speciﬁcation), middle two
days (during bud initiation) or last two days (during bud elonga-
tion) of a seven day culture period in medium containing andro-
gen (10 nM DHT) (Fig. 3A). UGS explants were then stained and
prostatic buds counted as described above (Fig. 3B). 5AzadC
signiﬁcantly increased bud number if administered during the
Fig. 2. DNA methylation restricts prostate bud number. (A) 14 dpc male UGSs were cultured for 2 days in the presence of DNA methylation inhibitor 50-aza-20-
deoxycytidine (5 μM, 5AzadC) alone followed by 5 days in medium containing androgen (10 nM dihydrotestosterone, DHT) alone. (B) Following culture tissues were stained
by ISH to visualize prostate bud marker NK-3 transcription factor locus 1 (Nkx3-1) (purple) and IHC to visualize all epithelium (E-cadherin, CDH1, brown). (C) Quantiﬁcation
of total prostatic bud number in control and 5AzadC treated samples. Results are mean7SE, n¼5/group. Asterisk indicates signiﬁcant difference from control pr0.05.
Abbreviations: bl, bladder.
Fig. 3. DNA methylation acts during speciﬁcation to restrict prostate bud
number. (A) 14 dpc male UGSs were cultured in medium containing androgen
(10 nM dihydrotestosterone, DHT) and DNA methylation inhibitor 50-aza-20-deox-
ycytidine (5 μM, 5AzadC) either on the ﬁrst, middle or last 2 days of culture.
(B) Tissues were stained by ISH for NK-3 transcription factor locus 1 (Nkx3-1)
(purple) to visualize prostate buds and IHC to visualize all epithelium (E-cadherin,
CDH1, brown). (C) Quantiﬁcation of total prostatic bud number in control and
5AzadC treated samples. Results are mean7SE, nZ3/group. Asterisk indicates
signiﬁcant difference from control pr0.05.
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ﬁrst two days of culture but not during the middle or last two days
(Fig. 3C). These results indicate that DNA methylation functions
during prostatic bud speciﬁcation, but not during bud initiation
and elongation, to control the number of prostatic buds formed.
DNA methylation controls the rate of androgen dependent prostatic
bud formation
We hypothesized inhibition of DNA methylation may augment
prostatic bud number by allowing an increased number of pro-
static buds to form during the earliest stages of prostatic ductal
development. To test this hypothesis, we exposed 14 dpc male
UGSs to a single two day pulse of 5AzadC or vehicle alone, and
then examined prostatic bud formation after one, three, or ﬁve
additional days of growth in medium containing androgens but no
5AzadC. UGS explants were stained and total prostatic bud
number quantiﬁed as described above (Fig. 4B). UGSs that were
pulse treated with 5AzadC showed signiﬁcantly more prostatic
buds at all three time points than control-treated UGSs (Fig. 4C).
Linear regression analysis revealed that 5AzadC-treated UGSs had
a signiﬁcantly greater rate of prostatic bud formation than control-
treated UGSs (Fig. 4D). These results suggest that DNA methylation
acts to control the timing and rate of androgen-induced prostatic
bud formation from the initial stages of prostate development.
DNA methylation controls androgen sensitivity during androgen
dependent prostate development
The number of prostatic buds formed in control C57BL/6J fetuses
is highly reproducible between individual mice (Sugimura et al.,
1986) and in explant cultures (Keil et al., 2012). Our results support
the hypothesis that DNA methylation is one factor that restricts the
quantity of prostatic buds formed. One possible mechanism by which
this restriction occurs is that DNA methylation regulates UGS
sensitivity to androgens. To examine this mechanism, we tested
whether inhibition of DNA methylation augments prostatic bud
formation in a low androgen environment. Male UGSs already exhibit
androgen-induced gene expression at 14 dpc (Abler et al., 2011). To
ensure that UGSs used in this experiment were naïve to high
androgen levels prior to the culture period, we used female UGSs,
which also form prostatic buds in response to androgens (Keil et al.,
2014; Cunha, 1975). Female UGSs were grown for two days in
medium containing 5AzadC (5 μM) or vehicle alone, followed by
ﬁve additional days in medium containing androgen alone. The
androgen concentration in this study (0.01 nM DHT) was 1000
lower than the concentration traditionally used to support prostate
morphogenesis in mouse UGS organ culture (Allgeier et al., 2010;
Vezina et al., 2008) and is lower than the DHT concentration
sufﬁcient to mimic the same budding response of UGSs cultured
with15–17 dpc testes or physiologically relevant concentrations of
testosterone (Lasnitzki and Mizuno, 1977). While female UGSs are
capable of forming small androgen independent buds (Vezina et al.,
2008), the addition of 5AzadC caused female UGSs to form
signiﬁcantly more buds (by at least two fold) versus control UGSs
(Fig. 5). These results indicate that DNA methylation regulates
prostatic bud formation at least in part by regulating androgen
sensitivity of the budding response.
Fig. 4. DNA methylation restricts rate of prostate bud formation. (A) 14 dpc
male UGSs were cultured for 2 days in the presence of DNA methylation inhibitor
50-aza-20-deoxycytidine (5 μM, 5AzadC) alone followed by 1, 3 or 5 additional days
in medium containing androgen (10 nM dihydrotestosterone, DHT) alone.
(B) Tissues were stained by ISH for prostate bud marker NK-3 transcription factor
locus 1 (Nkx3-1) (purple) and IHC to visualize all epithelium (E-cadherin, CDH1,
brown). (C) Quantiﬁcation of total buds formed at each timepoint. Results are
mean7SE, n¼5/group. Asterisk indicates signiﬁcant difference from control
pr0.05. (D) Linear regression of the rate of bud formation, analysis of covariance
revealed a signiﬁcant difference between treatment groups (p¼0.004). Abbrevia-
tions: bl, bladder.
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DNA methylation of the androgen receptor controls prostate bud
formation
We have shown that inhibition of DNA methylation via 5AzadC
enhances prostatic bud number and increases androgen sensitiv-
ity. One potential mechanism to explain both of these results is
that 5AzadC reduces Ar DNA methylation, thereby increasing
Ar mRNA and protein expression. The Ar gene locus contains a
1.5 kb CpG island that encompasses the transcription start site and
exon 1, a region that is actively methylated in humans and rodents
(Jarrard et al., 1998; Takahashi et al., 2002; Kim et al., 2013). DNA
methylation changes within this region have been demonstrated
in cell lines (Tian et al., 2012) and C57Bl/6 mouse tissues
(Kim et al., 2013). We used this known region of Ar DNA methyla-
tion to examine whether 5AzadC is capable of decreasing Ar DNA
methylation in mouse UGS explants, and to validate analytical
tools for assessing Ar DNA methylation. 14 dpc female UGS
explants were cultured in the presence of androgen alone or
androgen and 5AzadC, then pyrosequencing of bisulﬁte converted
DNA was performed on isolated UGS tissues. DNA methylation was
detected at all sites (Supplemental Fig. 2) and 5AzadC signiﬁcantly
reduced the percentage of DNA methylation at ﬁve of ﬁve CpG
sites in the region analyzed (Supplemental Fig. 2).
While pyrosequencing demonstrated decreased DNA methylation
of the Ar CpG region following 5AzadC treatment, this method cannot
discriminate between 5-methylcytosine and 5-hydroxymethylcyto-
sine, a base modiﬁcation that can mediate DNA demethylation
(Mohr et al., 2011) and that could potentially confound our results.
Therefore, we used methylated DNA immunoprecipitation followed by
QPCR (MeDIP-QPCR), a method speciﬁc to 5-methylcytosine-mediated
DNA methylation, to independently conﬁrm our pyrosequencing
results. Using QPCR primers designed to amplify the same region
examined by pyrosequencing, the MeDIP-QPCR results corroborated
our pyrosequencing results, showing that 5AzadC signiﬁcantly reduces
Ar DNA methylation in mouse UGS (Supplemental Fig. 2) and
validating use of MeDIP-QPCR for analysis of Ar DNA methylation in
this study.
We next used MeDIP-QPCR, along with RT-QPCR and immu-
nostaining, to test whether 5AzadC treatment inﬂuences Ar DNA
methylation status and mRNA and protein expression during
prostatic bud speciﬁcation. 14 dpc male UGS explants were cul-
tured for two days in the presence of androgens and either 5AzadC
or vehicle, after which Ar promoter DNA methylation was mea-
sured by MeDIP-QPCR. 5AzadC signiﬁcantly decreased Ar promoter
DNA methylation (Fig. 6A) and also increased Ar mRNA (Fig. 6B)
and protein abundance (Fig. 6C–F). 5AzadC treatment increased
the frequency of detectable AR staining in UGS epithelial cells by
almost 20%, detectable AR staining in KRT14þ basal epithelial cells
by nearly 10%, and detectable AR staining in UGS mesenchyme
cells by 10% (Fig. 6D–F). These results reveal that 5AzadC decreases
Ar promoter DNA methylation and increases AR expression,
suggesting a possible mechanism for the increased androgen
sensitivity of the prostatic budding response we observed.
Based on the above in vitro ﬁndings and the diminished
expression of Dnmts in mesenchyme from 14 dpc to 17 dpc (Fig. 1)
(Keil et al., 2013), we tested the hypothesis that Ar DNA methylation
also decreases in UGS mesenchyme over the course of prostate bud
formation. 14 and 17 dpc male UGS mesenchyme was isolated and
Ar promoter DNA methylation measured by MeDIP-QPCR. The Ar
promoter was more highly methylated in male UGS mesenchyme at
14 dpc compared to 17 dpc (Fig. 7A). This temporal change in Ar
DNA methylation coincides with an increase in UGS mesenchymal
Ar mRNA (Takeda and Chang, 1991) and protein expression from
14 dpc to 17 dpc (Fig. 7B and C). These results provide evidence
in vivo for the potential mechanism we identiﬁed with inhibiting
DNA methylation in vitro: Ar DNA methylation is diminished during
initiation of prostate development to trigger an increase in AR
expression and androgen-dependent prostatic bud formation.
Discussion
Our results suggest a link between DNA methylation and
androgen responsive prostatic bud growth through a mechanism
likely involving the AR. Inhibiting DNA methylation in the UGS
prior to prostatic bud formation decreases Ar promoter DNA
methylation, increases Ar mRNA and protein abundance, increases
UGS sensitivity to androgens, and causes the UGS to form prostatic
buds at an earlier stage and in greater number. These results
Fig. 5. DNA methylation controls developing prostate androgen sensitivity.
(A) 14 dpc female UGSs were cultured for 2 days in the presence of DNA
methylation inhibitor 50-aza-20-deoxycytidine (5 μM, 5AzadC) alone followed by
5 days in medium containing androgen (0.01 nM dihydrotestosterone, DHT) alone.
(B) Tissues were stained by ISH for prostate bud marker NK-3 transcription factor
locus 1 (Nkx3-1) (purple) and IHC to visualize all epithelium (E-cadherin, CDH1,
brown). (C) Quantiﬁcation of total bud number in control and 5AzadC tissues.
Results are mean7SE, n¼5/group. Asterisk indicates signiﬁcant difference from
control pr0.05. Arrowheads indicate epithelial buds.
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suggest that DNA methylation establishes a developmental check-
point that restricts UGS androgen sensitivity and responsiveness
prior to the onset of prostate development.
The tools for investigating mechanistic roles of DNA methyla-
tion at speciﬁc CpG loci are limited. We used a pharmacological
approach to identify prostate developmental phenotypes asso-
ciated with carefully timed exposure to a global DNA methylation
inhibitor, 5AzadC. While 5AzadC is capable of inhibiting DNA
methylation across the genome, other studies using this drug
reveal its scope of action on gene expression is surprisingly narrow
—often involving only a few hundred genes (Yamashita et al.,
2006). We previously used 5AzadC as a chemical probe to
demonstrate a crucial role for E-cadherin DNA methylation in
prostatic bud outgrowth (Keil et al., 2014). Here, using the same
approach but modifying the timing of 5AzadC exposure,
we revealed a second prostate development phenotype linked
to DNA methylation—the timing and scope of prostatic bud
formation. While we acknowledge that many potential DNA
methylation sites could contribute to this process, our collective
results point toward DNA methylation of the Ar promoter as
playing a key role in this process. Speciﬁcally, we showed that
5AzadC (1) increases the number of prostatic buds formed in
culture, (2) accelerates the rate of prostatic bud formation,
(3) causes a greater quantity of prostate buds to form under low
androgen concentrations, (4) signiﬁcantly decreases Ar promoter
DNA methylation, (5) signiﬁcantly increases Ar mRNA abundance
and (6) signiﬁcantly increases the percentage of AR protein-
positive cells in the UGS. We also conﬁrmed in vivo that Ar
promoter DNA methylation decreases from 14 to 17 dpc.
Our results indicate that the DNA methylation status of the male
mouse UGS prior to prostatic bud formation inﬂuences the pattern
and number of prostatic buds it will form. Several environmental
chemicals and estrogenic chemicals inappropriately inﬂuence pros-
tate budding and our new results may shed light on the mechanisms
Fig. 6. Androgen receptor (Ar) DNA methylation is correlated with mRNA and protein abundance. 14 dpc male UGSs were cultured for 2 days in the presence of DNA
methylation inhibitor 50-aza-20-deoxycytidine (5 μM, 5AzadC) or vehicle (0.1% DMSO) in medium containing androgen (10 nM dihydrotestosterone, DHT). (A) Ar DNA
methylation assessed by methylated DNA immunoprecipitation and normalized to IgG control. (B) Relative Ar mRNA abundance quantiﬁed by real time QPCR relative to
peptidyl prolyl isomerase a (Ppia). (C) AR protein (red) and basal epithelium (keratin 14, KRT14, green) were visualized using immunohistochemistry. Cell nuclei were
counterstained with DAPI (blue). Dotted line indicates the boundary between mesenchyme and epithelium. Quantiﬁcation of percent total AR positive cells in (D) all
epithelium (E) KRT14þ basal epithelium and (F) mesenchyme. Results are mean7SE, n¼5/group. Asterisk indicates signiﬁcant difference from control pr0.05.
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by which these chemicals act on the UGS to inﬂuence prostate
development. For example, bisphenol A (BPA), diethylstilbestrol and
2,3,7,8-tetrachlorodibenzo-p-dioxin modulate the number and pat-
tern of prostatic buds formed in fetal mice (Vezina et al., 2008;
Timms et al., 2005) and have separately been shown to inﬂuence
DNA methylation patterns in mouse UGS and elsewhere (Tang et al.,
2012; Li et al., 2003). BPA also increases AR expression in the UGS,
but the responsible mechanisms have not been identiﬁed (Richter
et al., 2007). Our new results suggest the intriguing hypothesis that
BPA, and potentially other estrogenic chemicals, may inﬂuence
prostatic bud formation by altering Ar DNA methylation in the UGS.
Fetal mouse prostatic bud formation trails the onset of testi-
cular testosterone synthesis by about three days. The cause for this
delay between onset of androgen synthesis and initiation of
androgen-dependent prostate bud formation is not known. We
showed that prostate androgen sensitivity and bud formation can
be enhanced in the presence of a DNA methylation inhibitor,
thereby revealing the possibility that DNA methylation of the Ar
promoter may account for this delay, safeguarding against pre-
cocious development of prostatic buds. How DNA methylation is
regulated in the UGS and whether DNA methylation continues to
control prostate androgen sensitivity throughout life is unknown.
Further, whether DNA methylation guides checkpoints of hormo-
nal responsiveness in other developing hormone responsive tis-
sues is yet to be determined.
An interesting ﬁnding resulting from our studies is that the
DNA methylation inhibitor enhanced AR expression not only in
UGS mesenchyme, where it is known to be necessary for prostate
development (Cunha, 1973), but also in UGS epithelium. There was
a 20% increase in AR positive cells in the epithelium of UGSs
treated with 5AzadC versus control and a 10% increase in mesench-
yme. AR is not required in UGS epithelium for prostate develop-
ment (Cunha, 1973), but the consequence of precocious epithelial
AR expression during prostatic bud formation has never been
examined. Determining the consequence of increased UGS epithe-
lial AR and whether changes in Ar DNA methylation in UGS
mesenchyme or epithelium are responsible for enhanced budding
in response to 5AzadC pose intriguing avenues of future study.
How DNA methylation of the Ar is reduced during the course of
prostate bud formation is unknown. Possible mechanisms include:
(1) Passive DNA demethylation whereby DNA methylation is not
maintained upon subsequent cell divisions potentially by down-
regulating DNMT1. (2) Active DNA demethylationwhich occurs when
methylated cytosines undergo base modiﬁcations that in turn trigger
DNA mismatch repair or base excision repair pathways, leading to
replacement with unmethylated cytosines. Several of the enzymes
capable of modifying methylated cytosines to trigger base excision
are present in the developing prostate (Keil et al., 2013). Whether one
or both of these mechanisms contributes to the decrease in Ar DNA
methylation during prostate development remains to be determined.
Fig. 7. Androgen receptor (Ar) DNA methylation is correlated with AR protein abundance in vivo. (A) UGS mesenchyme was isolated from 14 dpc and 17 dpc male UGS.
Ar DNA methylation assessed by methylated DNA immunoprecipitation and normalized to IgG control. (B,b) 14 dpc and (C,c) 17 dpc lower urinary tract sagittal sections were
stained by immunohistochemistry to visualize AR (red) E-cadherin protein (CDH1, green). Cell nuclei were stained with DAPI. Insets represent magniﬁed images.
Abbreviations: E, epithelium; M, mesenchyme. Results are mean7SE, n¼5/group. Asterisk indicates signiﬁcant difference from control pr0.05.
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